Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.43 |
| ▸ | PIM1 | P11309 | 12/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13340886 | 0.75 | PIM1 (0.53) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL219258 | 0.67 | PIM1 (0.53) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL13366364 | 0.67 | PIM1 (0.43) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL18711179 | 0.67 | PIM1 (0.42) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL18711250 | 0.67 | PIM1 (0.42) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL19928684 | 0.67 | PIM1 (0.42) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL18711226 | 0.67 | PIM1 (0.42) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL18711174 | 0.67 | PIM1 (0.42) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL18711177 | 0.67 | PIM1 (0.42) | IGF1RPIM1PIM2PIM3HPGD | |
| SCHEMBL19928658 | 0.67 | PIM1 (0.42) | IGF1RPIM1PIM2PIM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138838-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2017-03-08 | — | — | EP | disclosed |